Altheos Raises $20 Million Series A Round
Altheos Inc., a South San Francisco-based developer of small molecule drugs for unmet medical needs, has raised $20 million in Series A funding. Bay City Capital led the round, and was joined by Novo AS, Canaan Partners, Life Science Angels and Atheneos Capital. The company is initially focusing on compounds for glaucoma.
5 April 2010•4 mins read
